Welcome to MutualFunds.com. Please help us personalize your experience.

Select the one that best describes you

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission, we hope you enjoy your experience

HGHAX Hartford Healthcare A

  • Fund
  • HGHAX
  • Price as of: May 20, 2019
  • $32.68 - $0.15 - 0.46%
  • Category
  • Health & Biotech Equities

HGHAX - Profile

Vitals

  • YTD Return 8.6%
  • 3 Yr Annualized Return 1.0%
  • 5 Yr Annualized Return 0.5%
  • Net Assets $1.33 B
  • Holdings in Top 10 36.1%

52 WEEK LOW AND HIGH

$32.68
$28.19
$38.58

Expenses

OPERATING RELATED FEES

  • Expense Ratio 1.28%

SALES FEES

  • Front Load 5.50%
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 27.00%

TRADING FEES

  • Max Redemption Fee N/A

Min Investment

STANDARD (TAXABLE)

$2,000

IRA

$2,000

Investment Themes

CATEGORY

Health & Biotech Equities
  • Fund Type Open End Mutual Fund
  • Investment Style Health

Distributions

  • YTD Total Return 8.6%
  • 3 Yr Annualized Total Return 6.2%
  • 5 Yr Annualized Total Return 7.9%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -0.40%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name The Hartford Healthcare Fund
  • Fund Family Name Hartford Mutual Funds
  • Inception Date May 01, 2000
  • Shares Outstanding N/A
  • Share Class A
  • Currency USD
  • Domiciled Country United States
  • Manager Ann C. Gallo

Fund Description

Under normal circumstances, the fund invests at least 80% of its assets in the equity securities of health care-related companies worldwide as selected by the sub-adviser, Wellington Management Company LLP ("Wellington Management"). The fund takes a broad approach to investing in the health care sector. It may invest in health-related companies, including companies in the pharmaceuticals, biotechnology, medical delivery, medical products, medical services, managed health care, health information services and emerging health-related subsectors.

HGHAX - Performance

Return Ranking - Trailing

Period HGHAX Return Category Return Low Category Return High Rank in Category (%)
YTD 8.6% -4.3% 27.1% 26.47%
1 Yr -7.7% -23.4% 7.2% 67.65%
3 Yr 1.0%* -16.9% 24.9% 65.69%
5 Yr 0.5%* -11.4% 18.4% 58.16%
10 Yr 10.8%* -1.8% 16.1% 35.80%

* Annualized


Return Ranking - Calendar

Period HGHAX Return Category Return Low Category Return High Rank in Category (%)
2018 -10.3% -25.3% 7.7% 68.63%
2017 15.5% -10.8% 43.9% 58.82%
2016 -17.2% -29.8% 2.6% 63.73%
2015 -1.9% -20.4% 13.8% 47.06%
2014 18.1% -5.8% 31.5% 40.82%

Total Return Ranking - Trailing

Period HGHAX Return Category Return Low Category Return High Rank in Category (%)
YTD 8.6% -4.3% 27.1% 26.47%
1 Yr -7.7% -23.4% 11.3% 70.59%
3 Yr 6.2%* -16.9% 28.1% 46.08%
5 Yr 7.9%* -11.4% 20.4% 31.63%
10 Yr 14.8%* -1.8% 18.6% 30.86%

* Annualized


Total Return Ranking - Calendar

Period HGHAX Return Category Return Low Category Return High Rank in Category (%)
2018 -10.3% -25.3% 12.3% 71.57%
2017 21.7% -10.8% 45.8% 49.02%
2016 -8.6% -24.2% 8.7% 31.37%
2015 12.5% -16.6% 15.2% 10.78%
2014 26.3% -5.8% 36.7% 42.86%

NAV & Total Return History

HGHAX - Holdings

Concentration Analysis

HGHAX Category Low Category High HGHAX % Rank
Net Assets 1.33 B 13.9 M 44.3 B 40.20%
Number of Holdings 98 28 362 33.33%
Net Assets in Top 10 497 M 7.98 M 18.8 B 54.90%
Weighting of Top 10 36.05% 24.7% 76.6% 71.57%

Top 10 Holdings

  1. Abbott Laboratories 5.35%

  2. UnitedHealth Group Inc 4.61%

  3. Anthem Inc 4.18%

  4. Thermo Fisher Scientific Inc 3.47%

  5. Boston Scientific Corp 3.32%

  6. Eli Lilly and Co 3.31%

  7. Medtronic PLC 3.25%

  8. Bristol-Myers Squibb Company 3.08%

  9. Danaher Corp 2.78%

  10. Seattle Genetics Inc 2.70%


Asset Allocation

Weighting Return Low Return High HGHAX % Rank
Stocks
93.86% 92.71% 99.87% 94.12%
Cash
6.14% 0.00% 7.28% 4.90%
Preferred Stocks
0.00% 0.00% 2.00% 55.88%
Other
0.00% -1.35% 3.29% 65.69%
Convertible Bonds
0.00% 0.00% 0.12% 46.08%
Bonds
0.00% 0.00% 0.09% 50.98%

Stock Sector Breakdown

Weighting Return Low Return High HGHAX % Rank
Healthcare
91.14% 13.80% 99.84% 79.41%
Technology
1.45% 0.00% 61.10% 37.25%
Industrials
0.79% 0.00% 10.61% 15.69%
Utilities
0.00% 0.00% 0.00% 44.12%
Real Estate
0.00% 0.00% 2.13% 50.98%
Financial Services
0.00% 0.00% 3.44% 56.86%
Energy
0.00% 0.00% 0.08% 46.08%
Communication Services
0.00% 0.00% 0.00% 44.12%
Consumer Defense
0.00% 0.00% 0.40% 50.98%
Consumer Cyclical
0.00% 0.00% 7.87% 57.84%
Basic Materials
0.00% 0.00% 0.47% 52.94%

Stock Geographic Breakdown

Weighting Return Low Return High HGHAX % Rank
US
79.49% 62.33% 99.20% 58.82%
Non US
14.37% 0.00% 37.50% 50.98%

HGHAX - Expenses

Operational Fees

HGHAX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 1.28% 0.10% 2.98% 52.94%
Management Fee 0.85% 0.09% 1.25% 73.53%
12b-1 Fee 0.25% 0.00% 1.00% 26.09%
Administrative Fee N/A 0.01% 0.40% N/A

Sales Fees

HGHAX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load 5.50% 2.50% 5.75% 59.26%
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

HGHAX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 0.75% 2.00% N/A

Turnover Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

HGHAX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 27.00% 0.00% 699.00% 24.51%

HGHAX - Distributions

Dividend Yield Analysis

HGHAX Category Low Category High HGHAX % Rank
Dividend Yield 0.00% 0.00% 0.01% 54.90%

Dividend Distribution Analysis

HGHAX Category Low Category High Category Mode
Dividend Distribution Frequency Annually Annually Annually Annually

Dividend Payout History


Net Income Ratio Analysis

HGHAX Category Low Category High HGHAX % Rank
Net Income Ratio -0.40% -2.15% 1.48% 56.86%

Capital Gain Distribution Analysis

HGHAX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Annually Annually

HGHAX - Managers

Ann C. Gallo

Manager

Start Date

Tenure

Tenure Rank

May 01, 2000

19.01

19.0%

Ann C. Gallo, Senior Managing Director, and Global Industry Analyst of Wellington Management, joined as an investment professional in 1998. Prior to that, Ann was a health care analyst with BT Alex. Brown (1995 — 1998). She was an investment banker and a health care analyst at Piper Jaffray in Minneapolis (1992 — 1995). Previously, she was a financial analyst with Citibank N.A. (1991 — 1992) and an accountant with Coopers & Lybrand (1987 — 1989). Ann received her MS from the Massachusetts Institute of Technology and her BS in accounting from Boston College.


Jean M. Hynes

Manager

Start Date

Tenure

Tenure Rank

May 01, 2000

19.01

19.0%

Jean M. Hynes, CFA, Senior Managing Director and Global Industry Analyst of Wellington Management, has been involved in portfolio management and securities analysis for the health science portion of the Fund since August 2003. Jean holds a BA in economics from Wellesley College (1991). She joined Wellington Management upon her graduation. She holds the Chartered Financial Analyst designation, and is a member of the CFA Institute and the Boston Security Analysts Society.


Robert L. Deresiewicz

Manager

Start Date

Tenure

Tenure Rank

May 01, 2000

19.01

19.0%

Robert L. Deresiewicz, Senior Managing Director, and Global Industry Analyst of Wellington Management, joined as an investment professional in 2000. Prior to that, Bob was an Assistant Professor of Medicine at the Harvard Medical School, and an Associate Physician in the Division of Infectious Diseases at the Brigham and Women's Hospital (1990 — 1998). Bob received his MBA from the Harvard Business School (2000), his MD from the Mount Sinai School of Medicine, and his BA in biochemistry summa cum laude from Columbia University.


Tenure Analysis

Category Low

0.09

Category High

21.64

Category Average

10.34

Category Mode

19.01